Contact us EN FR


Mucopolysaccharidosis type IIIA (MPS IIIA), or Sanfilippo syndrome type A, is a rare inherited neurodegenerative lysosomal storage disorder characterized by intractable behavioural problems and developmental regression resulting in early death. It is caused by mutations in the SGSH gene, which encodes an enzyme called Heparan-N-sulfamidase necessary for heparan sulfate (HS) recycling in cells. The disrupted lysosomal degradation and resulting storage of HS and glycolipids such as gangliosides leads to severe neurodegeneration. MPS IIIA affects about 1 in 100,000 new-borns and is inherited in an autosomal recessive pattern. There is currently no treatment.

More information on MPS III can be obtained from the MPS patient organizations and Orphanet.

Lysogene’s MPS IIIA gene therapy clinical trial strategy includes a partnership with the MPS patient networks to ensure families are well informed about our development program and are able to make informed choices concerning the best treatment strategy for their children. More information on our MPS IIIA clinical trials.

PDF download

guide V Anglaise-1

Download PDF in English
Download PDF in French
Download PDF in Portuguese
Download PDF in Deutsch

Latest tweet

Get in touch

Follow us

Join our mailing list

arrow-left arrow-right calendar contact download facebook linkedin location play reset rss twitter youtube